Details for New Drug Application (NDA): 021227
✉ Email this page to a colleague
NDA 021227 describes CANCIDAS, which is a drug marketed by Merck and is included in one NDA. It is available from one supplier. Additional details are available on the CANCIDAS profile page.
The generic ingredient in CANCIDAS is caspofungin acetate. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.
The generic ingredient in CANCIDAS is caspofungin acetate. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.
Summary for 021227
| Tradename: | CANCIDAS |
| Applicant: | Merck |
| Ingredient: | caspofungin acetate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 021227
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227 | NDA | Merck Sharp & Dohme LLC | 0006-3822 | 0006-3822-10 | 1 VIAL, SINGLE-USE in 1 CARTON (0006-3822-10) / 10.8 mL in 1 VIAL, SINGLE-USE |
| CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227 | NDA | Merck Sharp & Dohme LLC | 0006-3823 | 0006-3823-10 | 1 VIAL, SINGLE-USE in 1 CARTON (0006-3823-10) / 10.8 mL in 1 VIAL, SINGLE-USE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | 50MG/VIAL | ||||
| Approval Date: | Jan 26, 2001 | TE: | AP | RLD: | Yes | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | 70MG/VIAL | ||||
| Approval Date: | Jan 26, 2001 | TE: | AP | RLD: | Yes | ||||
Expired US Patents for NDA 021227
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-001 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-001 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-002 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-002 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-002 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-001 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-002 | Jan 26, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
